Ocular Therapeutix Begins Enrollment for Phase 3 Clinical Trial for Dextenza
Ocular Therapeutix announced enrollment of the first patients in a phase 3 clinical trial to evaluate the safety and efficacy of Dextenza (sustained-release dexamethasone, 0.4 mg) for the treatment of allergic conjunctivitis, according to a company news release. Dextenza is administered by a physician as a bioresorbable int...